Sarepta Therapeutics Inc. Common Stock (DE) (SRPT)
SRPT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$16.51
-5.33% on the day
Market cap
$1.7B
Small cap
Revenue · 2025
$2.2B
+15.6% on 2024
Net income · 2025
-$713.4M
-32.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SRPT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000873303 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.2B |
| Net income | -$713.4M |
| Operating income | -$699.8M |
| Net margin | -32.5% |
| Operating margin | -31.8% |
| Revenue growth | +15.6% |
| Cash | $801.3M |
| Total assets | $3.3B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-03-03 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-09-23 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.8% |
| 1 month | -18.8% |
| 3 months | -2.3% |
| Year to date | -21.8% |
| 1 year | -23.4% |
| From 52-week high | -31.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BRVE | Braveheart Bio Inc. | $19.33 | -5.06% | $1.7B |
| XNCR | Xencor Inc. | $23.52 | -6.07% | $1.7B |
| TRVI | Trevi Therapeutics Inc. | $12.29 | -4.95% | $1.8B |
| BHVN | Biohaven Ltd. Common Shares | $11.42 | -3.30% | $1.7B |
| ZYME | Zymeworks Inc. | $25.07 | -1.03% | $1.8B |
| SEPN | Septerna Inc. | $36.41 | -3.05% | $1.7B |
| MRVI | Maravai LifeSciences Holdings Inc. | $6.53 | -7.51% | $1.7B |
| AGIO | Agios Pharmaceuticals Inc. | $30.21 | -1.98% | $1.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier